Please assess the completion status of the following clinical trial:

Trial Title: COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Probable or confirmed infection by SARS-CoV2~* Intubated and mechanically ventilated~* Moderate/severe ARDS defined by the Berlin criteria (PaO2/FiO2 ≤200mmHg with PEEP ≥5cmH20)~* Onset of moderate/severe ARDS in less than 48 hours before randomization~Exclusion Criteria:~* Pregnancy or active lactation~* Known history of dexamethasone allergy~* Daily use of corticosteroids in the past 15 days~* Clinical indication for corticosteroids use for other diseases (i.e refractory septic shock)~* Patients who did use corticosteroids during hospital stay for periods equal or greater than two days~* Use of immunosuppressive drugs~* Cytotoxic chemotherapy in the past 21 days~* Neutropenia due to hematological or solid malignancies with bone marrow invasion~* Patient expected to die in the next 24 hours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention group (Type: EXPERIMENTAL): Dexamethasone. After randomization, dexamethasone \[20mg IV 1x/day for 5 days, followed by 10mg IV 1xd for 5 days\] + standard treatment (according to the treatment protocol for 2019-nCoV infection).
- Control (Type: NO_INTERVENTION): Standard treatment (according to the treatment protocol for 2019-nCoV infection).

Based on this trial design, predict the completion outcome and termination type (if applicable).